Intervention not reported
Quality of life (QoL) · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and an intermediate or poor risk according to the International…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Progression‐free survival (PFS) ‐ Network (subnet 1) included 10 pairwise comparisons ‐ Median · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and an intermediate or poor risk according to the International…
1 finding from 1 review
Intervention not reported
IMDC risk group · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the International Metastatic…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Overall survival (OS) ‐ Network (subnet 1) included 5 pairwise comparisons ‐ Median · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the International Metastatic…
1 finding from 1 review
Intervention not reported
Serious adverse events · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the International Metastatic…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival (PSF) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
Sorafenib showed no clear difference in progression‐free survival (absolute effect size estimates based on… compared with sunitinib (targeted agent versus targeted agent) (low certainty).
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 24 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Tivozanib showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with sorafenib (targeted agent versus targeted agent) (low certainty).
1 finding from 1 review
Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Tivozanib may leads to lower serious adverse events (Grade 3 or 4) compared with sorafenib (targeted agent versus targeted agent) (low certainty).
1 finding from 1 review
Health‐related quality of life · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
1 finding from 1 review
Progression‐free survival · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
Sorafenib probably leads to higher progression‐free survival (absolute effect size estimates based on… compared with pazopanib (targeted agent versus targeted agent) (moderate certainty).
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 24 months) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
Sorafenib showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with pazopanib (targeted agent versus targeted agent) (low certainty).
1 finding from 1 review
Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
It is very uncertain whether sorafenib changes serious adverse events (Grade 3 or 4) compared with pazopanib (targeted agent versus targeted agent) (very low certainty).
1 finding from 1 review
Health‐related quality of life (mean change value) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
1 finding from 1 review
Progression‐free survival · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
Sunitinib probably leads to lower progression‐free survival (absolute effect size estimates based on… compared with everolimus (targeted agent versus targeted agent) (moderate certainty).
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 24 months) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
Sunitinib showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with everolimus (targeted agent versus targeted agent) (low certainty).
1 finding from 1 review
Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
Sunitinib probably leads to higher serious adverse events (Grade 3 or 4) compared with everolimus (targeted agent versus targeted agent) (moderate certainty).
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 24 months) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
It is very uncertain whether sorafenib changes overall survival (absolute effect size estimates based on survival… compared with sunitinib (targeted agent versus targeted agent) (very low certainty).
1 finding from 1 review
Health‐related quality of life · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
1 finding from 1 review
Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
It is very uncertain whether sorafenib changes serious adverse events (Grade 3 or 4) compared with sunitinib (targeted agent versus targeted agent) (very low certainty).
1 finding from 1 review
Progression‐free survival · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
It is very uncertain whether sunitinib changes progression‐free survival (absolute effect size estimates based on… compared with IMA901 + sunitinib (targeted agent versus tumour vaccine + targeted… (very low certainty).
1 finding from 1 review